New data suggest that current recommendations overstate the proportion of patients who would receive significant kidney ...

In a report released on September 5, Joseph Schwartz from Leerink Partners reiterated a Buy rating on Travere Therapeutics (TVTX – ...

or Kidney Disease: Improving Global Outcomes (KDIGO) risk class. In addition, Ozempic was also shown to reduce the risk of death from any cause constantly in subgroups defined by eGFR and KDIGO ...

The inclusion of Travere’s drug, sparsentan, in the new KDIGO IgAN Draft Guidelines is a significant endorsement, as it suggests the drug’s efficacy in managing IgAN, a kidney disease that can ...

or Kidney Disease: Improving Global Outcomes (KDIGO) risk class. In addition, Ozempic was also shown to reduce the risk of death from any cause constantly in subgroups defined by eGFR and KDIGO risk ...

Diagnosis of CKD according to the criteria of the National Kidney Foundation (NFK) -NKF-KDOQI (2002) and NFK-KDIGO (2013) (28, 29), and clinical manifestations, (c) Not currently receiving chronic ...

We expect inclusion of NEFECON® in the Kidney Disease: Improving Global Outcomes ("KDIGO") 2024 guidelines as well as in the first Chinese guideline for IgAN in the second half of 2024.

Introduction Patients with advanced kidney disease (AKD) have to make difficult treatment modality ... The search for guidelines will include searches on the platforms of the KDIGO association, the ...